The Office of National Drug Control Policy (ONDCP) is an agency in the Executive Office of the President that coordinates federal efforts to reduce illegal drug use and its consequences. The office advises the President, develops national strategy documents, sets priorities for federal drug-control spending, and evaluates how programs across departments work together to address supply, demand, prevention, treatment and recovery.
Role and responsibilities
ONDCP prepares the annual National Drug Control Strategy and an associated budget summary that communicates the administration’s priorities for countering drug threats. The office monitors federal agency performance against strategy goals and seeks interagency alignment to improve coherence and efficiency. The director of ONDCP, a presidential appointee whose position is often called the "Drug Czar," represents the office in discussions with Congress, federal agencies, states and communities.
History and legal basis
Congress established ONDCP in 1988 to strengthen coordination of national anti‑drug activities and to provide clear federal policy guidance. Its legislative mandate directs the office to set policy priorities, track federal expenditures on drug-control programs, and report on progress to the President and to Congress.
Programs, partnerships and organization
ONDCP works with federal, state and local agencies, community coalitions and international partners. It administers or supports programs intended to disrupt trafficking, build prevention capacity, expand access to treatment and promote recovery services. The office provides grant support and policy coordination for initiatives that cross jurisdictional boundaries, and it convenes stakeholders to share data and best practices.
Assessment and public debate
National drug-control policy has been the subject of ongoing debate. Observers and policymakers differ over the proper balance between law enforcement, public health, harm reduction and treatment-focused approaches. Evaluations of ONDCP emphasize the importance of measurable outcomes, transparent budgeting and continued collaboration among diverse agencies to respond to changing drug trends and public-health challenges.